65,437 trials
Nicotine Dependence · Opiate Dependence
Primary: Number of Participants Who Experienced Seven-day Point Prevalence Smoking Abstinence — 3; 0 Participants
Ileostomy - Stoma · Colostomy
Primary: Leakage Under the Baseplate (cm^2) — 9.2; 6.6 cm2
Psoriasis
Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 — 0; 80.6 Percentage of participants…
Endometriosis
Primary: Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment — 52.1; 78.2; 32.6; 64.4 percentage of participants
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy) — 415.8; 355.9; 117.2…
PONV
Primary: Number of Participants With Complete Response — 78; 54 Participants — p=0.033
Cystic Fibrosis · Bronchiectasis
Primary: TV — 0.93; 1.00; 1.07 L
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
TTR-mediated Amyloidosis · Amyloidosis, Hereditary · Amyloid Neuropathies, Familial
Primary: Modified Neuropathy Impairment Score +7 (mNIS+7) — -6.03; 27.96 score on a scale — p=<0.0000001
Heart Failure
Primary: Change From Baseline in the Diffusing Capacity of the Lung for Carbon Monoxide (DLco) on Pulmonary Gas Transfer (Site: Mayo) — 0.6; 1.4; -0.4; 0.6 mL/mmHg/min
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Patients With Dose Limiting Toxicities — 0; 0; 2; 0 Participants
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale -5 (CAPS-5) PTSD Severity — 35.8; 37.9; 20.4; 35.3 units on a scale
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Diseases
Primary: Clinical Response (Complete and Partial) — 0; 4; 4; 5 Participants
Lymphoma, Follicular
Primary: Area Under the Concentration (AUC) Time Curve of BI 695500 and Rituximab (MabThera®) Over the First Dosing Interval (Pre-infusion on Day 1 to Pre-infusion on Day 8)…
Healthy Volunteers
Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration — 22.37; -18.09; -50.59; -75.26 Percent change in…